1-methyl-2-[(1-methylvinyl)thio]benzene

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 1-methyl-2-[(1-methylvinyl)thio]benzene
• 英文别名: 1-Methyl-2-prop-1-en-2-ylsulfanylbenzene
• 化学式: C₁₀H₁₂S
• 分子量: 164.271
• InChiKey: QGSJSBRAXATDAM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  25.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  碘甲烷 、 苯基乙烯基硫醚 在 正丁基锂 、 四甲基乙二胺 作用下， 以 乙醚 、 正己烷 为溶剂， 反应 2.0h， 以30%的产率得到1-methyl-2-[(1-methylvinyl)thio]benzene
  参考文献：
  名称：

  金属化反应。二十四。（乙烯基硫代）苯的金属化

  摘要：

  将有机锂化合物加到（乙烯基硫代）苯（1）中，然后进行亲电淬火，然后进一步金属化/亲电淬火是在一个罐中制备用等价或不同基团被邻位α-取代的邻位（烷硫基）苯的一般方法。的直接dimetalation 1次，得到邻，α- -dilithiated物种15之外的其它副产物。从15开始，可以一步获得邻位的α-取代的（乙烯基硫代）苯和杂环化合物。

  DOI：

  10.1016/s0040-4020(98)00869-2

文献信息

• [EN] C20-C21 SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTS<br/>[FR] AGONISTES DU RÉCEPTEUR DE GLUCOCORTICOÏDE SUBSTITUÉS EN C20-C21
  申请人：SCHERING CORP

  公开号：WO2009085879A2

  公开（公告）日：2009-07-09

  The present invention provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, esters, prodrugs, tautomers, or isomers of said compounds), having general structure (I); wherein L, R1, R2, R3, R4, R5, and R6 are selected independently of each other and as defined herein. The present invention also provides compounds (and salts, solvates, esters, prodrugs, tautomers, and isomers) of Formulas II, III, IV, V, and Vl, as defined herein. Also provided are pharmaceutical compositions, methods of preparing, and methods of using such compounds in the treatment and prophylaxis of a wide range of immune, autoimmune, and inflammatory diseases and conditions.

  本发明提供了具有一般结构（I）的化合物，以及该化合物的药用盐、溶剂合物、酯、前药、互变体或异构体（包括L、R1、R2、R3、R4、R5和R6在内独立选择的定义）。本发明还提供了根据本文所定义的化合物（和盐、溶剂合物、酯、前药、互变体和异构体）的II、III、IV、V和VI式化合物。还提供了药物组合物、制备方法以及利用这些化合物在治疗和预防各种免疫、自身免疫和炎症性疾病和症状中的方法。
• Novel Compounds for Imaging Tau Proteins That Accumulate In Brain
  申请人：National Institute of Radiological Sciences

  公开号：US20150239878A1

  公开（公告）日：2015-08-27

  The present invention provides a compound represented by the following formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof. wherein: R 1 and R 2 are each separately selected from the group consisting of hydrogen, alkyl, alkenyl, acyl, and hydroxyalkyl; R 3 is hydrogen or halogen; ring A is a benzene ring or a pyridine ring; ring B is selected from the group consisting of the following formulas (i), (ii), (iii), and (iv): in the formula (ii), R a is alkyl; R 4 and R 5 are each separately selected from the group consisting of hydrogen, hydroxy, alkoxy, haloalkoxy, halohydroxyalkoxy, and aminoalkyl; and [Formula 3] represents a double bond or a triple bond. The above compound can be used as a molecular probe for imaging tau proteins that accumulate in the brain.

  本发明提供了一种化合物，其表示为以下式子（I），其药学上可接受的盐或其溶剂化物。其中：R1和R2各自独立地选择自氢，烷基，烯基，酰基和羟基烷基的群组；R3是氢或卤素；环A是苯环或吡啶环；环B选择自以下式子（i），（ii），（iii）和（iv）的群组：在式子（ii）中，Ra是烷基；R4和R5各自独立地选择自氢，羟基，烷氧基，卤代烷氧基，卤代羟基烷氧基和氨基烷基的群组；以及[公式3]表示双键或三键。以上化合物可用作成像在脑中积累的tau蛋白的分子探针。
• QUINOLONE COMPOUND
  申请人：Otsuka Pharmaceutical Co., Ltd.

  公开号：EP3318557A2

  公开（公告）日：2018-05-09

  The present invention provides a compound represented by the formula (I) wherein X is a hydrogen atom or a fluorine atom; R is a hydrogen atom or alkyl; R1 is (1) cyclopropyl optionally substituted by 1 to 3 halogen atoms or (2) phenyl optionally substituted by 1 to 3 halogen atoms; R2 is alkyl, alkoxy, haloalkoxy, a halogen atom, cyano, etc.; and R3 is 7-oxo-7,8-dihydro-1,8-naphthyridinyl, 3-pyridyl, etc., or a salt thereof. The compound of the present invention has excellent antimicrobial activity against Clostridium difficile and is useful for the prevention or treatment of intestinal infection such as Clostridium difficile-associated diarrhea.

  本发明提供了一种由式 (I) 表示的化合物 其中 X 是氢原子或氟原子；R 是氢原子或烷基；R1 是(1)任选被 1 至 3 个卤素原子取代的环丙基或(2)任选被 1 至 3 个卤素原子取代的苯基；R2 是烷基、烷氧基、卤代烷氧基、卤素原子、氰基等；R3 是 7-氧代-7,8-二氢-1,8-萘啶基、3-吡啶基等或其盐。本发明的化合物对艰难梭菌具有优异的抗菌活性，可用于预防或治疗艰难梭菌相关性腹泻等肠道感染。
• POLYMERIZABLE COMPOUND, POLYMERIZABLE COMPOSITION, POLYMER, AND OPTICALLY ANISOTROPIC MATERIAL
  申请人：Zeon Corporation

  公开号：EP3483141A2

  公开（公告）日：2019-05-15

  The present invention relates to: a hydrazine compound represented by formula (3), wherein Ax and Ay have the meanings indicated in claims 1 to 5; a method for producing an optically anisotropic article by (i) obtaining a polymerizable compound by reacting the hydrazine compound with a carbonyl compound, (ii) forming an alignment film on a substrate, and (iii) forming a liquid crystal layer on the alignment film using the polymer obtained by polymerizing the polymerizable compound or a polymerizable composition including the polymerizable compound and an initiator; and a method for producing a polymerizable compound represented by formula (I), by reacting the hydrazine compound with a carbonyl compound represented by formula (4). The film thus obtained has a low melting point, excellent solubility, is capable of being manufactured at low cost, and capable of uniform polarized light conversion across a broad wavelength region.

  本发明涉及一种由式(3)表示的肼化合物，其中Ax和Ay具有权利要求1至5所述的含义；一种生产光学各向异性制品的方法，其方法是：(i)通过使肼化合物与羰基化合物反应获得可聚合化合物，(ii)在基底上形成配位膜，(iii)使用通过聚合可聚合化合物或包括可聚合化合物和引发剂的可聚合组合物获得的聚合物在配位膜上形成液晶层；以及一种通过使肼化合物与式(4)代表的羰基化合物反应生产式(I)代表的可聚合化合物的方法。由此获得的薄膜熔点低、溶解性好、制造成本低，并能在宽波长区域内实现均匀的偏振光转换。
• COMPOSITIONS AND METHODS FOR DRUG SENSITIZATION OF PARASITES
  申请人：The Texas A&M University System

  公开号：EP3659597A2

  公开（公告）日：2020-06-03

  The present invention relates to arylphenoxypropionate derivatives, aryloxyphenoxyacetate derivatives, aryloxyphenylacetate derivatives, substituted quinols, or pharmaceutically acceptable salts, hydrates, or prodrugs thereof, or combinations thereof that can be used in the inhibition of parasites.

  本发明涉及可用于抑制寄生虫的芳基苯氧基丙酸酯衍生物、芳基苯氧基乙酸酯衍生物、芳基苯氧基乙酸酯衍生物、取代喹啉，或其药学上可接受的盐、水合物或原药，或其组合。